Connect with us

Industry News

Blueberries Medical to Collaborate with the International Research Center on Cannabis and Mental Health in New York for Product Formulation and the Development of Treatment-Focused Medical Education Programs

Avatar

Published

on

default_cannabis_industry_cannamaps

TORONTO, April 15, 2019 (GLOBE NEWSWIRE) — Blueberries Medical Corp. (CSE: BBM) (OTCQB: BBRRF) (FRA: 1OA) (the “Company” or “Blueberries“) a Latin American licenced producer of medicinal cannabis and cannabis-derived products, has signed a definitive joint venture agreement (the “Agreement”) with the International Research Center on Cannabis and Mental Health (“IRCCMH” or the “Center”) for the development of medical education programs for physicians and patients in Latin America and product formulation.
IRCCMH is a leading research and academic organization in the cannabis sector with extensive experience in cannabis research and education, pharmacology, product formulation and the efficacy of cannabis-based treatments. Based in New York and aligned with the Silver School of Social Work at New York University, IRCCMH is comprised of renowned scientists, educators and clinicians and was created to bridge a gap between research and clinical practice. IRCCMH also creates education programs for physicians and patients and acts as advisor to several state-sponsored medical cannabis programs and has guided state regulators to create and implement cannabis programs in Pennsylvania, Delaware, New Jersey, Utah, California and other states. Founded by Jan Roberts, LCSW and Jahan Marcu, Ph.D, the Center’s founders and staff are regarded as thought leaders in the sector and have also been deeply involved with several other leading cannabis focused associations and are respected authors and speakers within the industry as further detailed below.“This collaboration agreement with IRCCMH provides an outstanding opportunity for Blueberries to leverage IRCCMH’s deep sector expertise to help educate physicians in Latin America and develop medical treatments for patients in the Latin American market and beyond. As cannabis regulation evolves globally, education and awareness are paramount to its adoption and the establishment of early mover advantages,” stated Dr. Patricio Stocker, Chief Executive Officer of the Company. “IRCCMH is a highly respected institution in the United States and their focus on education and research aligns with our goal of providing effective and responsible treatment to a broad spectrum of patients and customers globally. The agreement will emphasize education for prescribing doctors and patients and provide educational tools for all parties. This alliance will ensure that we are developing products and treatments that the medical community needs, with a streamlined process for reaching patients in these evolving markets.”IRCCMH will leverage its background and expertise to support the development of Blueberries’ commercial and educational initiatives. Together with IRCCMH, Blueberries is developing a treatment-focused medical education program designed to assist physicians in prescribing cannabis-based treatment plans to patients (the “Program”) in Latin America. A comprehensive patient and physician education program will be a cornerstone of Blueberries’ strategy for the introduction and adoption of cannabis-based treatments, positioning Blueberries as an early leader in the Latin American medicinal cannabis market.“IRCCMH is excited about our collaboration with Blueberries Medical and the opportunity to leverage our expertise in cannabis-based patient care, research and education in rapidly evolving global markets”, stated Jan Roberts, founder of IRCCMH stated, “This affiliation will help Blueberries position themselves in Latin America as a leader in medical cannabis treatment and will ensure that the research, education, and unique expertise of IRCCMH will impact a growing segment of medical treatment with cannabis in this region of the world.”This initiative will initially be rolled out through the company’s previously announced partnership with El Manantial Medical Centers in Bogota which will provide the platform, resources, patients and expertise needed to launch the Program and commercialize the formulations and products developed through the collaboration with the IRCCMH. Blueberries is further extending its patient & physician network currently, replicating the El Manantial Medical Center model with other physicians, institutions and medical associations.In addition to the development of best in class educational programs for the education of physicians and patients in Latin America, access to IRCCMH´s team of specialists with deep expertise in medical cannabis will facilitate faster product development and generate the appropriate formulations and product standardization to accelerate the commercialization of the Company’s medicinal cannabis products, initially through El Manantial Medical Center’s rapidly growing patient base and the Company’s other strategic arrangements.About IRCCMH & IRCCMH Founders
Based in New York and aligned with the Silver School of Social Work at NYU and building upon years of expertise working with cannabis and mental health in the United States, IRCCMH was created to bridge a gap between research and clinical practice. IRCCMH was co-founded by Jan Roberts and Dr. Jahan Marcu in 2017 to provide quality research and education to the medical cannabis community.  IRCCMH is a community-based institute in New York City that collaborates with universities, researchers, foundations, state institutions, and other organizations to leverage the best talent in the field. The Institute works to build educational seminars, expand research with universities, and provide consultation for healthcare professionals and regulatory organizations in order to improve patient care. Through its numerous projects, Marcu and Roberts have been instrumental in creating dialogues in areas of cannabis education and investigation that hadn’t been previously addressed. 
For more information visit www.irccmh.org/about-irccmh.Jan Roberts, LCSW: CEO & Director of Translational Research
Jan Roberts is a co-founder for IRCCMH and serves as CEO and Director of Translational Research. Ms. Roberts is a Licensed Clinical Social Worker who owns and operates one of the largest collaborative care practices in the mid-Atlantic region – Partners in Health and Wellbeing. Ms. Roberts is a clinician and an entrepreneur with an activist spirit who has extensive experience running both non-profit and for-profit healthcare organizations.
Ms. Roberts teaches at NYU Silver School of Social Work and is currently working on a funded study of Mental Health Clinicians and Knowledge and Attitudes on Cannabis.  She is also Guest-Editor for a Special Issue on Cannabis and Mental Health for the Clinical Social Work Journal (CSWJ). Ms. Roberts’ current work is focused on the clinical application of cannabis in mental health settings and focusing on maladaptive coping strategies rather than a substance-based approach to treating addictions. As a result, Ms. Roberts is especially interested in educating fellow mental health clinicians on the most recent research findings to address stigma and lack of knowledge related to cannabis, the endocannabinoid system and mental health outcomes.Jahan Marcu, Ph.D.: COO & Director of Experimental Pharmacology and Behavioral Research
Jahan Marcu, Ph.D., is a co-founder for IRCCMH. Dr. Marcu is the former Chief Science Officer at Americans for Safe Access (a medical cannabis advocacy non-profit) and former Director of the Patient Focused Certification program, which is a health and safety oversight program that assesses regulatory compliance at cannabis operations.
He is co-founder and past-chairman of the CANN subdivision of the Chemical Health and Safety Division (DCHAS) of the American Chemical Society. His is also on the Board of Directors of the International Association for Cannabinoids as Medicine.  He has a background in analytical chemistry and molecular pharmacology, and received his Ph.D. for contributions in characterizing the structure and function of the cannabinoid receptors. He is an author of the American Herbal Pharmacopeia’s Cannabis Monograph and serves on multiple expert government, trade association committees and scientific organizations.Dr. Marcu has helped create medical cannabis educational training for clinicians and for workers in the medical cannabis industry, and has been invited to speak at many international conferences and universities, including the University of Leiden, Temple University School of Medicine, Princeton Hospital, and Yale University. Dr. Marcu is also a court qualified expert witness on cannabis and synthetic cannabinoids.Dr. Marcu is a recipient of the Billy Martin research award from the International Cannabinoid Research Society.About Blueberries Medical Corp.
Blueberries is a Latin American licensed producer of naturally grown premium quality cannabis with its primary operations ideally located in the Bogotá Savannah of central Colombia and operations currently being established in Argentina. The Company is led by a specialized team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology and marketing, Blueberries is fully licensed for the cultivation, production, domestic distribution, and international export of CBD and THC-based medical cannabis in Colombia. Blueberries’ combination of leading scientific expertise, agricultural advantages and distribution arrangements has positioned the Company to become a leading international supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts and related products.
Additional information about the Company is available at www.blueberriesmed.com. For more information, please contact:Camilo Villalba, Chief Operating Officer
Tel: +57.313.483.0131
Email: cvillalba@blueberriesmed.com
Jessika Angarita, Pacta Relations
angarita@pactarelations.com
Tel: +1 (305) 877 4710
Cautionary Note Regarding Forward-Looking InformationThis news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward looking statements“) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking statements relate, among other things, to: expectations relating to the potential benefits of the Agreement and the Company’s partnership with the Center, expectations regarding the development and commercialization of the Company’s products, and future growth plans.These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Colombian and international medical cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in Colombia or internationally; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Original story can be found at: http://www.globenewswire.com/news-release/2019/04/15/1803902/0/en/Blueberries-Medical-to-Collaborate-with-the-International-Research-Center-on-Cannabis-and-Mental-Health-in-New-York-for-Product-Formulation-and-the-Development-of-Treatment-Focused.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

AsiaBaseMetals Inc. Provides Additional Information Regarding Previously Announced Cooperation Agreement

Avatar

Published

on

default_cannabis_industry_cannamaps

VANCOUVER, British Columbia, June 26, 2019 (GLOBE NEWSWIRE) — AsiaBaseMetals Inc. (the “Company”) (TSX-V: “ABZ”) wishes to provide additional information regarding the cooperation agreement (the “Agreement“) between the Company and a city (the “City“) within a member country (the “Country“) of the European Union (“EU“), as previously announced on June 19, 2019.
The Agreement provides for the City to apply for a licence for growing and selling cannabis for medical purposes (“Medical-Cannabis-Permit“) and, if it becomes permitted by law in the Country, a licence for the growing, processing and sale of cannabis for commercial purposes including recreational purposes (“Recreational-Cannabis-Permit“), through a limited liability company to be incorporated by the City (“City-New-Sub-Co-Ltd.“).  Upon City-New-Sub-Co-Ltd. obtaining a Medical-Cannabis-Permit or a Recreational-Cannabis-Permit, the City has agreed to transfer all or a majority of the shares of City-New-Sub-Co-Ltd. to the Company for a purchase price of up to approximately C$8,000 based on the current exchange rate.The City has informed the Company that it has commenced the process to incorporate City-New-Sub-Co-Ltd.The Company has spent approximately C$10,000 to date in regard to the Agreement, excluding legal fees, and has no financial obligations under the Agreement unless and until the Company acquires City-New-Sub-Co-Ltd. as noted above.  The Company is using its working capital to evaluate and pursue this and other mining and non-mining opportunities.There is no defined timeline for obtaining a Medical-Cannabis-Permit or Recreational-Cannabis-Permit and, unlike in Canada, completing the construction of a production facility is not required in order to apply for a Medical-Cannabis-Permit in the Country.  The Company has not designed or estimated costs to build a production facility or made a decision to build a production facility. For more information on the Agreement and the transactions contemplated therein, see the Company’s news release disseminated on June 19, 2019, a copy of which can be found on the Company’s profile on www.sedar.com.  Any transaction will be subject to receipt of regulatory approvals, including approval of the TSX Venture Exchange.For more information please email info@asiabasemetals.com.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Cautionary Note Regarding Forward-Looking Statements: Certain disclosure in this release, including statements regarding the Agreement, the transactions contemplated thereby and the Company’s pursuit of opportunities, may constitute “forward-looking information” within the meaning of Canadian securities legislation. In making the forward-looking statements in this release, the Company has applied certain factors and assumptions that the Company believes are reasonable, including that the Company will obtain the necessary regulatory approvals for the transactions contemplated by the Agreement, the Medical-Cannabis-Permit will be obtained, the acquisition of City-New-Sub-Co-Ltd. by the Company will be completed as expected and will have the benefits expected by management. However, the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such uncertainties and risks include, among others, financing risks, delays in obtaining or inability to obtain required regulatory approvals, the Medical-Cannabis-Permit will not be obtained, the Company will not be able to use the working capital to pay associated costs with the Agreement or Medical-Cannabis Permit, as applicable, the acquisition of City-New-Sub-Co-Ltd. by the Company will not be completed as expected or will not have the benefits expected by management and changes in the Company’s plans. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned not to place undue reliance on forward-looking statements. The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.  There can be no assurance that the transaction contemplated by the Agreement will complete on the anticipated terms or at all.Contact Information

AsiaBaseMetals Inc.
Raj Chowdhry, Chief Executive Officer
Email:

Original story can be found at: http://www.globenewswire.com/news-release/2019/06/26/1874839/0/en/AsiaBaseMetals-Inc-Provides-Additional-Information-Regarding-Previously-Announced-Cooperation-Agreement.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

American Herbal Products Association Hosts Inaugural Hemp-CBD Dietary Supplement Congress in Denver on August 15-16

Avatar

Published

on

default_cannabis_industry_cannamaps

Denver, CO, June 26, 2019 (GLOBE NEWSWIRE) —The American Herbal Products Association (AHPA) is presenting a unique, two-day Hemp-CBD Supplement Congress in Denver this August to provide critical input for companies navigating the rapidly evolving legal, regulatory and financial landscapes to manufacture and market dietary supplement products with hemp or hemp-derived ingredients including cannabidiol (CBD). The event features presentations from Federal officials, including speakers from the FDA and USDA who will provide insights into their agencies’ approach to regulating hemp-CBD and supplements made with these ingredients. According to the latest research, hemp-CBD sales are projected to surpass $15 – 20 billion in the U.S. by 2024, indicating an immediate need for manufacturers and retailers to understand the role of hemp in the dietary supplement category. “The U.S. market for hemp-derived CBD in dietary supplements is growing and evolving rapidly and companies that manufacture and sell CBD supplements face a host of challenges and opportunities. AHPA’s Congress will provide companies with the information needed to successfully navigate challenges and take advantage of opportunities,” explains AHPA President Michael McGuffin. “FDA and USDA officials will join legal and industry experts to provide compliance strategies for dietary supplement regulatory requirements to help companies meet the growing consumer demand for high-quality, safe products.”AHPA’s Hemp-CBD Congress features a full-day of presentations and discussions on Friday, August 16 and two, half-day workshops on Thursday, August 15 that will cover:How to comply with FDA’s current good manufacturing practice (cGMP) requirements for dietary supplements – training by EAS Consulting Group.New dietary ingredient (NDI) notifications and generally recognized as safe (GRAS) for hemp as a food additive and dietary ingredient – presented by AIBMR Life SciencesIndustry experts and government officials will present on a host of issues impacting Hemp-CBD companies, including:Getting to Market: Hemp Supply Chain ManagementOvercoming Regulatory Obstacles: Updates from the FDA, USDA and Individual StatesPrimer on FDA Regulation of Hemp-CBD SupplementsThe Hemp-CBD Supplement Market: A Financial SnapshotHemp-CBD Supplements from the Retailers’ PerspectiveNotable sessions include a presentation from USDA Agricultural Marketing Service (AMS) senior marketing specialist William Richmond, who will provide an update on USDA efforts related to the recent decriminalization of hemp. In addition, the FDA will provide an update on the agency’s ongoing efforts to design and implement a regulatory framework to ensure informed access to safe, legal products. This session is sponsored by Greenspoon Marder LLP and will be moderated by Jessica Wasserman, a partner in the International, Government Relations and Cannabis Law practice.USDA Speaker Bio – Bill RichmondBill Richmond leads the USDA, Agricultural Marketing Service, Specialty Crops Program in Washington, D.C. and is responsible for establishment and implementation of the U.S. Domestic Hemp Production Program. In this role, he is responsible for rulemaking, public education, and stakeholder outreach. In prior roles, Bill was the Acting Director of the USDA team responsible for establishing new labeling rules for bioengineered (GMO) foods in the U.S., served as the Chief of Staff of the Agricultural Marketing Service from 2016-2018, and led the Colorado dairy field office. Event DetailsWhere: Crowne Plaza Denver, 1450 Glenarm Pl, Denver, CO 80202When: Thursday, August, 15 & Friday, August, 16, 2019Register for the Congress: http://bit.ly/HempCBDCongressBecome a Sponsor PartnerYour tax-deductible sponsorship of AHPA’s Hemp-CBD Supplement Congress supports the important work of the American Herbal Products Association. Sponsors will be recognized in all marketing materials, PR and onsite throughout the event. For information on individual and corporate sponsorships, contact Amber Bennett at abennett@ahpa.org.About AHPAThe American Herbal Products Association (AHPA) is the national trade association and voice of the herbal products industry. AHPA is comprised of more than 400 member companies, consisting primarily of domestic and foreign companies doing business as growers, processors, manufacturers and marketers of herbs and herbal products as foods, dietary supplements, cosmetics, and non-prescription drugs, and also including companies that provide expert services to the herbal trade. Founded in 1982, AHPA’s mission is to promote the responsible commerce of herbal products to ensure that consumers continue to enjoy informed access to a wide variety of herbal goods. www.AHPA.orgMedia and Press Pass ContactSteve Hoffman, Compass Natural — steve@compassnaturalmarketing.com — (303) 807-1042# # #AttachmentsWilliam Bill Richmond USDA SMALLHemp-CBD Congress Sponsors verticalHaley Chitty (media inquires)
American Herbal Products Association (AHPA)
301-588-1171 x104
communications@ahpa.org

Original story can be found at: http://www.globenewswire.com/news-release/2019/06/26/1874682/0/en/American-Herbal-Products-Association-Hosts-Inaugural-Hemp-CBD-Dietary-Supplement-Congress-in-Denver-on-August-15-16.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

EnWave and Aurora Cannabis Expand Scope of Machine Delivery to Achieve Good Manufacturing Practice (GMP) Standards

Avatar

Published

on

default_cannabis_industry_cannamaps

VANCOUVER, British Columbia, June 26, 2019 (GLOBE NEWSWIRE) — EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) reports today that Aurora Cannabis Inc. (“Aurora”) (TSX: ACB) (NYSE: ACB), is expanding the scope of requirements for its potential purchase of a third 120kW Radiant Energy Vacuum (“REV™”) machine targeted for its European operations in Denmark. Aurora Nordic Cannabis, a subsidiary of Aurora, plans to develop a pharmaceutical-level GMP facility, which requires several upgrades to the contemplated machinery.  These upgrades will be confirmed as soon as possible and will also increase the economic profile of this prospective equipment purchase.
On April 26, 2019, EnWave and Aurora announced that the companies had entered into a royalty-bearing commercial license agreement with sub-licensing rights, providing Aurora with the exclusive rights to EnWave’s patented REV™ drying technology for the production of cannabis materials in the European Union, excluding Portugal (the “European License”).Aurora intends to pursue widespread adoption of the REV™ technology throughout its global operations to capture the significant advantages of EnWave’s drying technology when compared to traditional drying methods. Benefits of REV™ Technology in the Cannabis IndustryEnWave’s patented REV™ technology is a rapid, low temperature, continuous drying method that maintains optimal terpene levels, flavour, as well as other product attributes during the drying process. The company’s vacuum-microwave technology enables fast, uniform drying with flexible final moisture content; capabilities that are unattainable with freeze drying or air drying.In the cannabis industry, REV™ technology provides for capital expenditure savings on drying space (smaller footprint) and related HVAC investments, as well as the ability to free up space, which can be repurposed to increase the economic output of each facility.  Furthermore, EnWave’s REV™ technology reduces drying time from 5-7 days to less than two hours, resulting in significant working capital savings and speed to market of product. The technology has certain additional benefits, including the support of industrial scale flow-though, accelerating the ability for large-scale processing of cannabis and CBD-rich biomass into intermediate or finished product.About EnWaveEnWave Corporation, a Vancouver-based advanced technology company, has developed Radiant Energy Vacuum (“REV™”) – an innovative, proprietary method for the precise dehydration of organic materials. EnWave has further developed patent-pending methods for uniformly drying and decontaminating cannabis through the use of REV™ technology, shortening the time from harvest to marketable cannabis products. REV™ technology’s commercial viability has been demonstrated and is growing rapidly across several market verticals in the food, and pharmaceutical sectors including legal cannabis. EnWave’s strategy is to sign royalty-bearing commercial licenses with industry leaders in multiple verticals for the use of REV™ technology. The company has signed over twenty royalty-bearing licenses to date, opening up nine distinct market sectors for commercialization of new and innovative products. In addition to these licenses, EnWave has formed a Limited Liability Corporation, NutraDried Food Company, LLC, to develop, manufacture, market and sell all-natural cheese snack products in the United States under the Moon Cheese® brand. EnWave has introduced REV™ as the new dehydration standard in the food and biological material sectors: faster and cheaper than freeze drying, with better end product quality than air drying or spray drying. EnWave currently has three commercial REV™ platforms:nutraREV® which is used in the food industry to dry food products quickly and at low-cost, while maintaining high levels of nutrition, taste, texture and colour;powderREV® which is used for the bulk dehydration of food cultures, probiotics and fine biochemicals such as enzymes below the freezing point, andquantaREV® which is used for continuous, high-volume low-temperature drying.An additional platform, freezeREV®, is being developed as a new method to stabilize and dehydrate biopharmaceuticals such as vaccines and antibodies. More information about EnWave is available at www.enwave.net.EnWave CorporationMr. Brent Charleton, CFA
President and CEO
For further information:Brent Charleton, CFA , President and CEO at +1 (778) 378-9616
E-mail: bcharleton@enwave.net
Dan Henriques, CPA, Chief Financial Officer at +1 (604) 835-5212
E-mail: dhenriques@enwave.net  
Deborah Honig, Corporate Development at + 1 (647) 203-8793
E-mail: dhonig@enwave.net
Safe Harbour for Forward-Looking Information Statements: This press release may contain forward-looking information based on management’s expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company’s strategy for growth, product development, market position, expected expenditures, and the expected synergies following the closing are forward-looking statements. All third party claims referred to in this release are not guaranteed to be accurate. All third party references to market information in this release are not guaranteed to be accurate as the Company did not conduct the original primary research. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions. No statement in this press release should be construed as a waiver of any party’s rights, and all such rights are reserved. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Original story can be found at: http://www.globenewswire.com/news-release/2019/06/26/1874676/0/en/EnWave-and-Aurora-Cannabis-Expand-Scope-of-Machine-Delivery-to-Achieve-Good-Manufacturing-Practice-GMP-Standards.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Trending